# CureVac: Phase 1 study withdrawn (Squamous NSCLC)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | CureVac |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC) |
| NCT ID | NCT07073183 |
| Phase | Phase 1 |
| Status | withdrawn |
| Conditions | Squamous NSCLC |
| Intervention types | biological |
| Site countries | United States, France, Spain |
| Posted | 2025-07-18 |
| Planned start | 2025-07-30 |
| Event | Withdrawn before enrolling |
| Event date | 2026-11-02 |
| Last update posted | 2026-11-02 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07073183). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.